Y. Ning

617 total citations
23 papers, 499 citations indexed

About

Y. Ning is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Y. Ning has authored 23 papers receiving a total of 499 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Y. Ning's work include Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (4 papers) and Prostate Cancer Treatment and Research (4 papers). Y. Ning is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (4 papers) and Prostate Cancer Treatment and Research (4 papers). Y. Ning collaborates with scholars based in United States, United Kingdom and Japan. Y. Ning's co-authors include Edwin R. Sánchez, David H. Ledbetter, Jan P. Dumanski, Heather E. McDermid, Kevin Clark, Jonathan Flint, E.E. Baulieu, Kai Hoffmann, Stéphane Le Bihan and Christine Mercier-Bodard and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Y. Ning

21 papers receiving 487 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Y. Ning United States	12	292	119	105	75	71	23	499
Nicole Deutschmann Germany	12	305 1.0×	56 0.5×	111 1.1×	26 0.3×	49 0.7×	14	505
D.R. Jones United States	13	635 2.2×	88 0.7×	268 2.6×	56 0.7×	73 1.0×	20	919
Jantina Manning Australia	15	462 1.6×	79 0.7×	56 0.5×	86 1.1×	102 1.4×	33	737
Adrienne S. McCampbell United States	12	253 0.9×	80 0.7×	105 1.0×	64 0.9×	29 0.4×	15	537
Jeffery Stevens United States	5	552 1.9×	230 1.9×	159 1.5×	46 0.6×	20 0.3×	5	819
Jiaxin Wu China	8	431 1.5×	129 1.1×	65 0.6×	66 0.9×	57 0.8×	24	578
Christina Rudduck Australia	14	233 0.8×	111 0.9×	96 0.9×	45 0.6×	17 0.2×	26	442
Candida Zuchegna Italy	12	422 1.4×	78 0.7×	94 0.9×	253 3.4×	60 0.8×	20	737
Robert Dante France	17	572 2.0×	232 1.9×	118 1.1×	43 0.6×	29 0.4×	30	730
Miia M. Rytinki Finland	13	693 2.4×	117 1.0×	253 2.4×	104 1.4×	132 1.9×	15	842

Countries citing papers authored by Y. Ning

Since Specialization

Citations

This map shows the geographic impact of Y. Ning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y. Ning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y. Ning more than expected).

Fields of papers citing papers by Y. Ning

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y. Ning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y. Ning. The network helps show where Y. Ning may publish in the future.

Co-authorship network of co-authors of Y. Ning

This figure shows the co-authorship network connecting the top 25 collaborators of Y. Ning. A scholar is included among the top collaborators of Y. Ning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y. Ning. Y. Ning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Jiaqi, et al.. (2025). The piR-31115-PIWIL4 complex promotes the migration of the triple-negative breast cancer cell lineMDA-MB-231 by suppressing HSP90AA1 degradation. Gene. 942. 149255–149255.

Nadal, Rosa, Amir Mortazavi, Mark N. Stein, et al.. (2017). Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. Annals of Oncology. 28. v295–v295. 19 indexed citations

Litwin, Alain H., Linda Agyemang, Matthew J. Akiyama, et al.. (2017). The PREVAIL Study: intensive models of HCV care for people who inject drugs. Journal of Hepatology. 66(1). S72–S72. 18 indexed citations

Nadal, Rosa, Howard L. Parnes, Lisa M. Cordes, et al.. (2016). A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC). Annals of Oncology. 27. vi272–vi272. 2 indexed citations

Apolo, Andrea B., Amir Mortazavi, Mark N. Stein, et al.. (2016). A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors. Annals of Oncology. 27. vi266–vi266. 12 indexed citations

Hochheiser, Harry, Y. Ning, Andrés S. Hernández, et al.. (2016). Using Nonexperts for Annotating Pharmacokinetic Drug-Drug Interaction Mentions in Product Labeling: A Feasibility Study. JMIR Research Protocols. 5(2). e40–e40. 5 indexed citations

Sebio, Ana, Souta Matsusaka, W Zhang, et al.. (2015). Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer. The Pharmacogenomics Journal. 16(4). 312–319. 13 indexed citations

Bohanes, Pierre, Dongyun Yang, Fotios Loupakis, et al.. (2014). Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. The Pharmacogenomics Journal. 15(3). 226–234. 12 indexed citations

Winder, Thomas, Georgios Giamas, P. M. Wilson, et al.. (2013). Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen. The Pharmacogenomics Journal. 14(1). 28–34. 30 indexed citations

10.

Winder, Thomas, P. M. Wilson, Dongyun Yang, et al.. (2012). An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence. The Pharmacogenomics Journal. 13(4). 342–348. 5 indexed citations

11.

Huang, Xuanzhang, Y. Ning, James L. Gulley, et al.. (2011). Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 29(7_suppl). 138–138. 7 indexed citations

12.

Ning, Y., et al.. (2010). FDA accelerated approval of anticancer agents.. Journal of Clinical Oncology. 28(15_suppl). 6065–6065.

13.

Ning, Y., Philip M. Arlen, James L. Gulley, et al.. (2007). A phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). Journal of Clinical Oncology. 25(18_suppl). 5114–5114. 17 indexed citations

14.

Aragon‐Ching, Jeanny B., Y. Ning, Lea Latham, et al.. (2007). Osteonecrosis of the jaw (ONJ) in androgen-independent prostate cancer (AIPC) patients receiving ATTP (bevacizumab, docetaxel, thalidomide, and prednisone). Journal of Clinical Oncology. 25(18_suppl). 19594–19594. 3 indexed citations

15.

Ning, Y., Philip M. Arlen, James L. Gulley, et al.. (2006). A phase II trial of docetaxel, thalidomide, bevacizumab, and prednisone in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). Journal of Clinical Oncology. 24(18_suppl). 13037–13037. 5 indexed citations

16.

Ning, Y., Jonathan Flint, Kevin Clark, et al.. (1997). Molecular characterization of a 130-kb terminal microdeletion at 22q in a child with mild mental retardation.. PubMed. 60(1). 113–20. 107 indexed citations

17.

Ning, Y., et al.. (1996). In vivo evidence for the generation of a glucocorticoid receptor-heat shock protein-90 complex incapable of binding hormone by the calmodulin antagonist phenoxybenzamine.. Molecular Endocrinology. 10(1). 14–23. 8 indexed citations

18.

Ning, Y. & Edwin R. Sánchez. (1995). Evidence for a Functional Interaction Between Calmodulin and the Glucocorticoid Receptor. Biochemical and Biophysical Research Communications. 208(1). 48–54. 29 indexed citations

19.

Renoir, Jack Michel, Christine Mercier-Bodard, Kai Hoffmann, et al.. (1995). Cyclosporin A potentiates the dexamethasone-induced mouse mammary tumor virus-chloramphenicol acetyltransferase activity in LMCAT cells: a possible role for different heat shock protein-binding immunophilins in glucocorticosteroid receptor-mediated gene expression.. Proceedings of the National Academy of Sciences. 92(11). 4977–4981. 76 indexed citations

20.

Ning, Y. & Edwin R. Sánchez. (1993). Potentiation of glucocorticoid receptor-mediated gene expression by the immunophilin ligands FK506 and rapamycin.. Journal of Biological Chemistry. 268(9). 6073–6076. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact